<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="173757">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00833963</url>
  </required_header>
  <id_info>
    <org_study_id>H4621g</org_study_id>
    <nct_id>NCT00833963</nct_id>
  </id_info>
  <brief_title>An Observational Study of Pregnancy And Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta In Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior To Conception (MotHER)</brief_title>
  <acronym>MotHER</acronym>
  <official_title>An Observational Study of Pregnancy And Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta In Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior To Conception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      The MotHER Pregnancy Registry is a U.S.-based, prospective, observational cohort study in
      women with breast cancer who have been or are being treated with herceptin plus perjeta with
      or without pertuzumab, or ado-trastuzumab emtansine, during pregnancy or within 7 months
      prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or
      ado-trastuzumab emtansine exposure).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>21 Months</target_duration>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Pregnancy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study is recruiting patients from anywhere within the United States. No office visits
        are required to participate in this registry. Information is collected from patients based
        on their medical charts.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant; women identified at any trimester of pregnancy may enroll in this study as
             long as enrollment occurs prior to experiencing pregnancy outcome

          -  Exposure to at least one dose of trastuzumab (as adjuvant or metastatic treatment),
             pertuzumab plus trastuzumab combination treatment, or ado-trastuzumab emtansine
             during pregnancy or within 7 months prior to conception

          -  United States resident

          -  Patient has provided verbal or written informed consent (on her own behalf and on
             behalf of her child)

        Exclusion Criteria:

          -  Prior knowledge of pregnancy outcome at time of enrollment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikki Brown, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>INC Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MotHER Registry Coordinating Center www.themotherpregnancyregistry.com</last_name>
    <phone>800-690-6720</phone>
  </overall_contact>
  <location>
    <facility>
      <name>MotHER Registry Coordinating Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 21, 2014</lastchanged_date>
  <firstreceived_date>January 30, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herceptin</keyword>
  <keyword>MBC</keyword>
  <keyword>BC</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>childbirth</keyword>
  <keyword>Perjeta</keyword>
  <keyword>Kadcyla</keyword>
  <keyword>pertuzumab</keyword>
  <keyword>ado-trastuzumab emtansine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ado-trastuzumab emtansine</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
